eIF4A

PF3D7_1468700 (eIF4A) is a cytoplasmic DEAD-box ATP-dependent RNA/DNA helicase that serves as the helicase component of the P. falciparum eIF4F cap-binding translation initiation complex (PMID:19751846, PMID:21331256). It is incorporated into eIF4F through direct interaction with eIF4G, which independently binds eIF4E and PABP to assemble the initiation scaffold, and eIF4A co-localizes with eIF4E in the cytoplasm of intraerythrocytic-stage parasites (PMID:19751846, PMID:21331256). Purified recombinant eIF4A displays Mg2+-dependent, bipolar nucleic acid unwinding activity with a ~2-fold preference for the 3'-to-5' direction and basal ATP turnover that is stimulated by single- or double-stranded nucleic acid but does not unwind blunt-ended duplexes (PMID:22750398). eIF4A is required for parasite proliferation: combined dsRNA knockdown of eIF4A and eIF4E inhibits growth more than either alone (PMID:21331256). The protein is a validated antimalarial target of rocaglate compounds (CR-1-31B, silvestrol), which perturb its association with RNA and block translation initiation, with defined active in vitro and in vivo antiplasmodial activity across Plasmodium species (PMID:29463745, PMID:37291191). Beyond its role in cap-dependent initiation and rocaglate targeting, no further mechanistic detail — including the specific post-translational modifications inferred to generate multiple developmental isoforms — has been characterized in the available corpus (PMID:19091060, PMID:34890716).

1. 2008 Low

   Before functional dissection, it was unknown whether eIF4A exists as a single form or is developmentally modulated; proteomic profiling showed multiple isoforms with distinct temporal abundance, raising the possibility of PTM-generated functional diversity during the erythrocytic cycle.

   Evidence 2D-DIGE with mass spectrometry identification and quantitative time-course profiling of synchronized schizont-stage parasites

   PMID:19091060

   Open questions at the time

   • Specific post-translational modifications not identified
   • Functional consequence of distinct isoforms not tested
   • Isoform assignment inferred from spot pattern rather than direct modification mapping
2. 2009 Medium

   It was unclear how eIF4A integrated into the parasite translation machinery; biochemical interaction data placed it within the canonical eIF4F complex via eIF4G, which also binds eIF4E and PABP.

   Evidence Biochemical isolation and protein-protein interaction mapping of eIF4G binding sites

   PMID:19751846

   Open questions at the time

   • No reciprocal Co-IP or structural validation of the eIF4A:eIF4G interface
   • Stoichiometry and assembly kinetics of eIF4F not determined
3. 2010 Medium

   The subcellular site of action and essentiality of eIF4A were unresolved; co-localization with eIF4E and a combinatorial knockdown growth defect established it as a cytoplasmic, proliferation-essential factor.

   Evidence Immunofluorescence co-localization and dsRNA knockdown of eIF4A and eIF4E with growth assays

   PMID:21331256

   Open questions at the time

   • dsRNA specificity/off-target effects not fully controlled
   • Single-gene essentiality via genetic knockout not established
   • Contribution of eIF4A vs eIF4E to the combined phenotype not separable
4. 2012 Medium

   The intrinsic enzymatic properties of eIF4A were undefined; in vitro assays on purified recombinant protein demonstrated Mg2+-dependent bipolar unwinding with 3'-to-5' preference and nucleic-acid-stimulated ATPase activity.

   Evidence Helicase unwinding, ATPase, and substrate-specificity assays with purified recombinant codon-optimized eIF4A

   PMID:22750398

   Open questions at the time

   • Assays performed on DNA substrates rather than mRNA in a translation context
   • No structural basis for directional preference
   • Physiological substrate not identified
5. 2018 Medium

   Whether eIF4A was a druggable antimalarial target was untested; the rocaglate CR-1-31B was shown to disrupt eIF4A:RNA association and block initiation with potent in vitro and in vivo antiplasmodial activity.

   Evidence RNA-binding perturbation assay, ex vivo P. falciparum replication, and in vivo P. berghei and P. chabaudi mouse models

   PMID:29463745

   Open questions at the time

   • Direct binding to eIF4A vs an eIF4A-containing complex not fully separated in vivo
   • Selectivity over host eIF4A not quantified
   • Resistance mechanisms not mapped
6. 2021 Low

   Whether eIF4A associates with the mRNA 5' cap complex biochemically was addressed; cap affinity proteomics detected eIF4A, consistent with eIF4F membership but with low reproducibility.

   Evidence 5' cap affinity matrix pulldown with LC-MS/MS of asexual-stage lysates

   PMID:34890716

   Open questions at the time

   • Low reproducibility of eIF4A detection
   • No functional validation of cap association
   • Indirect vs direct cap-complex recruitment not resolved
7. 2023 Medium

   The molecular determinants of rocaglate sensitivity were unconfirmed; thermal shift and docking validated silvestrol engagement and six critical eIF4A residues as binding determinants.

   Evidence In vitro thermal shift assay with recombinant eIF4A, molecular docking of eIF4A:RNA:rocaglate complexes, and in vitro antiplasmodial testing

   PMID:37291191

   Open questions at the time

   • Predicted binding residues not validated by mutagenesis
   • No experimental co-crystal structure of the eIF4A:RNA:rocaglate complex
   • Docking energies are computational predictions

• The specific post-translational modifications generating eIF4A isoforms and the physiological mRNA targets whose translation depends on eIF4A helicase activity remain unresolved.
• No modification mapping of the observed isoforms
• No genome-wide identification of eIF4A-dependent transcripts
• No high-resolution structure of parasite eIF4A alone or in eIF4F